AngioDynamics Inc Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Can you hear me okay? So the first question is the current wave of COVID is -- feels like it's very different from anything else and you have the dubious honor of being the first company to really present some numbers. Maybe your last quarter didn't really get hit as much by Omicron, but as we sit here in the middle, as we're getting into January and this is hitting into full swing, it might be helpful if you could maybe compare and contrast how this wave of COVID is different versus the prior and impact on your business and then -- that you've seen thus far? And then secondly, you talked about the $4 million backlog, kind of, was that any specific product line? And what product lines what is -- did that relate to? And then have you fulfilled and shipped those products?

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : And then if I could, just as we think about the impact of Omicron in the quarter, and you've reiterated the revenue guidance of $310 million to $315 million, but should we think that this is going to have a pretty significant impact on the February-ended quarter? And maybe we'll see -- I think historically, you're down maybe 1 to 2 percentage points sequentially at least last fiscal year. I mean, could we see a more pronounced effect this year given Omicron as we think about just the February quarter?